Market Cap 4.19B
Revenue (ttm) 1.19B
Net Income (ttm) 2.00M
EPS (ttm) N/A
PE Ratio 16.83
Forward PE 11.40
Profit Margin 0.17%
Debt to Equity Ratio -1.56
Volume 1,112,500
Avg Vol 2,478,264
Day's Range N/A - N/A
Shares Out 125.02M
Stochastic %K 28%
Beta 0.75
Analysts Strong Sell
Price Target $46.40

Company Profile

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sub...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 804 379 1040
Address:
10710 Midlothian Turnpike, Suite 125, North Chesterfield, United States
topstockalerts
topstockalerts May. 4 at 8:37 PM
Indivior PLC shares rose Monday after the company announced a $175 million accelerated share repurchase (ASR) agreement with Barclays Bank PLC. The ASR is part of Indivior’s previously authorized $400 million buyback program and reflects confidence in its long-term strategy, cash flow generation, and disciplined capital allocation. Under the deal, Indivior will make an upfront $175 million payment and expects to receive an initial delivery of 3,717,473 shares. The final number of shares will depend on the volume-weighted average price during the ASR period, minus a discount. Final settlement is expected by the end of June 2026. The company said the ASR will not impact its previously issued financial guidance. The remaining $100 million under the buyback authorization may be used for additional repurchases depending on market conditions. $INDV
0 · Reply
OpenOutcrier
OpenOutcrier May. 4 at 12:12 PM
$INDV (+2.9% pre) Indivior launches $175M accelerated share buyback https://ooc.bz/l/100901
0 · Reply
goldenbluey
goldenbluey Apr. 30 at 6:04 PM
$INDV retail is really sleeping on this one
1 · Reply
OpenOutcrier
OpenOutcrier Apr. 30 at 12:30 PM
$INDV (+8.4% pre) Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance https://ooc.bz/l/100560
0 · Reply
howardlindzon
howardlindzon Apr. 30 at 12:16 PM
$INDV $4 billion FEW followers the best trends … this one biotech
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 30 at 11:06 AM
$INDV Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $3.55 up 86.84% YoY • Reported revenue of $317M up 19.17% YoY • Indivior raised its full-year 2026 financial guidance, now expecting 2026 total SUBLOCADE net revenue growth of 13% year-over-year and adjusted EBITDA growth of 50% year-over-year at the midpoint of its ranges.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 28 at 4:11 AM
$INDV RSI: 66.41, MACD: 0.5947 Vol: 1.37, MA20: 31.81, MA50: 31.88 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
levy42088
levy42088 Apr. 27 at 3:22 PM
$INDV great company great product but takes so long to find a bottom after ipo. Was holding for months at 15$ but assumed market was priced correctly if it was that low for that long
0 · Reply
Doozio
Doozio Apr. 25 at 2:09 PM
$INDV 10/30 gap still controls the pattern. chop chop da huckleberries are below da YUGE $$$ for another eps gap n go thru da $$$ ONTO 🐒🍌🧠⏰♾️. 🖕opioids.
0 · Reply
mehul75
mehul75 Mar. 14 at 2:01 AM
$INDV volume breakout
0 · Reply
Latest News on INDV
Indivior Announces $175 Million Accelerated Share Repurchase

May 4, 2026, 7:00 AM EDT - 9 days ago

Indivior Announces $175 Million Accelerated Share Repurchase


Indivior reports Q1 EPS 96c, consensus 66c

2026-04-30T12:00:16.000Z - 13 days ago

Indivior reports Q1 EPS 96c, consensus 66c


Indivior announces proposed convertible senior notes offering

2026-03-12T11:37:31.000Z - 2 months ago

Indivior announces proposed convertible senior notes offering


Indivior Announces Proposed Convertible Senior Notes Offering

Mar 12, 2026, 7:00 AM EDT - 2 months ago

Indivior Announces Proposed Convertible Senior Notes Offering


Indivior reports Q4 non-GAAP EPS 82c, consensus 67c

2026-02-26T12:22:19.000Z - 2 months ago

Indivior reports Q4 non-GAAP EPS 82c, consensus 67c


Indivior board authorizes $400M share repurchase program

2026-02-26T12:21:31.000Z - 2 months ago

Indivior board authorizes $400M share repurchase program


Indivior to Participate in Upcoming Investor Conferences

Feb 24, 2026, 7:00 AM EST - 2 months ago

Indivior to Participate in Upcoming Investor Conferences


Indivior announces completion of redomiciliation to U.S.

2026-01-26T12:15:54.000Z - 3 months ago

Indivior announces completion of redomiciliation to U.S.


Indivior price target raised to $50 from $40 at Northland

2026-01-20T14:10:48.000Z - 4 months ago

Indivior price target raised to $50 from $40 at Northland


Indivior price target raised to $48 from $35 at H.C. Wainwright

2026-01-12T11:05:07.000Z - 4 months ago

Indivior price target raised to $48 from $35 at H.C. Wainwright


Indivior sees FY26 revenue $1.125B-$1.195B, consensus $1.19B

2026-01-08T12:05:28.000Z - 4 months ago

Indivior sees FY26 revenue $1.125B-$1.195B, consensus $1.19B


Indivior Announces Inclusion in the S&P SmallCap 600® Index

Dec 22, 2025, 7:00 AM EST - 5 months ago

Indivior Announces Inclusion in the S&P SmallCap 600® Index


Indivior price target raised to $36 from $28 at Morgan Stanley

2025-12-03T11:53:28.000Z - 5 months ago

Indivior price target raised to $36 from $28 at Morgan Stanley


Indivior concludes legacy U.S. Department of Justice matter

2025-11-20T21:06:06.000Z - 6 months ago

Indivior concludes legacy U.S. Department of Justice matter


Indivior Concludes Legacy U.S. Department of Justice Matter

Nov 20, 2025, 4:01 PM EST - 6 months ago

Indivior Concludes Legacy U.S. Department of Justice Matter


Indivior management to meet with Craig-Hallum

2025-11-19T17:20:10.000Z - 6 months ago

Indivior management to meet with Craig-Hallum


Indivior price target raised to $41 from $34 at Craig-Hallum

2025-10-31T13:32:25.000Z - 6 months ago

Indivior price target raised to $41 from $34 at Craig-Hallum


Indivior to Participate in the Stifel 2025 Healthcare Conference

Oct 28, 2025, 10:00 AM EDT - 7 months ago

Indivior to Participate in the Stifel 2025 Healthcare Conference


UK's Indivior to re-domicile to US after listing move

Oct 1, 2025, 9:35 AM EDT - 8 months ago

UK's Indivior to re-domicile to US after listing move


Indivior to Participate in Upcoming Investor Events

Aug 20, 2025, 12:00 PM EDT - 9 months ago

Indivior to Participate in Upcoming Investor Events


Indivior Appoints Tony Kingsley to the Board of Directors

Jun 24, 2025, 4:12 PM EDT - 11 months ago

Indivior Appoints Tony Kingsley to the Board of Directors


Indivior Announces Patrick Barry as Chief Commercial Officer

May 27, 2025, 8:30 AM EDT - 1 year ago

Indivior Announces Patrick Barry as Chief Commercial Officer


Indivior Announces Q1 2025 Financial Results

Apr 24, 2025, 2:00 AM EDT - 1 year ago

Indivior Announces Q1 2025 Financial Results


Indivior Announces Further Changes to Board of Directors

Mar 4, 2025, 8:40 AM EST - 1 year ago

Indivior Announces Further Changes to Board of Directors


UK's Indivior appoints Joe Ciaffoni as CEO

Feb 27, 2025, 2:48 AM EST - 1 year ago

UK's Indivior appoints Joe Ciaffoni as CEO


UK's Indivior forecasts 17% decline in 2025 revenue

Feb 20, 2025, 2:55 AM EST - 1 year ago

UK's Indivior forecasts 17% decline in 2025 revenue


Indivior Announces FY and Q4 2024 Financial Results

Feb 20, 2025, 2:00 AM EST - 1 year ago

Indivior Announces FY and Q4 2024 Financial Results


topstockalerts
topstockalerts May. 4 at 8:37 PM
Indivior PLC shares rose Monday after the company announced a $175 million accelerated share repurchase (ASR) agreement with Barclays Bank PLC. The ASR is part of Indivior’s previously authorized $400 million buyback program and reflects confidence in its long-term strategy, cash flow generation, and disciplined capital allocation. Under the deal, Indivior will make an upfront $175 million payment and expects to receive an initial delivery of 3,717,473 shares. The final number of shares will depend on the volume-weighted average price during the ASR period, minus a discount. Final settlement is expected by the end of June 2026. The company said the ASR will not impact its previously issued financial guidance. The remaining $100 million under the buyback authorization may be used for additional repurchases depending on market conditions. $INDV
0 · Reply
OpenOutcrier
OpenOutcrier May. 4 at 12:12 PM
$INDV (+2.9% pre) Indivior launches $175M accelerated share buyback https://ooc.bz/l/100901
0 · Reply
goldenbluey
goldenbluey Apr. 30 at 6:04 PM
$INDV retail is really sleeping on this one
1 · Reply
OpenOutcrier
OpenOutcrier Apr. 30 at 12:30 PM
$INDV (+8.4% pre) Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance https://ooc.bz/l/100560
0 · Reply
howardlindzon
howardlindzon Apr. 30 at 12:16 PM
$INDV $4 billion FEW followers the best trends … this one biotech
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 30 at 11:06 AM
$INDV Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $3.55 up 86.84% YoY • Reported revenue of $317M up 19.17% YoY • Indivior raised its full-year 2026 financial guidance, now expecting 2026 total SUBLOCADE net revenue growth of 13% year-over-year and adjusted EBITDA growth of 50% year-over-year at the midpoint of its ranges.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 28 at 4:11 AM
$INDV RSI: 66.41, MACD: 0.5947 Vol: 1.37, MA20: 31.81, MA50: 31.88 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
levy42088
levy42088 Apr. 27 at 3:22 PM
$INDV great company great product but takes so long to find a bottom after ipo. Was holding for months at 15$ but assumed market was priced correctly if it was that low for that long
0 · Reply
Doozio
Doozio Apr. 25 at 2:09 PM
$INDV 10/30 gap still controls the pattern. chop chop da huckleberries are below da YUGE $$$ for another eps gap n go thru da $$$ ONTO 🐒🍌🧠⏰♾️. 🖕opioids.
0 · Reply
mehul75
mehul75 Mar. 14 at 2:01 AM
$INDV volume breakout
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 12 at 1:01 PM
$INDV (-5.8% pre) Indivior stock falls after convertible notes offering announced https://ooc.bz/l/96495
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 5 at 2:05 AM
$INDV Current Stock Price: $32.15 Contracts to trade: $32.0 INDV Mar 20 2026 Call Entry: $0.10 Exit: $0.15 ROI: 55% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 1:26 PM
$INDV RSI: 43.78, MACD: -0.2300 Vol: 0.69, MA20: 34.27, MA50: 34.70 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 26 at 12:11 PM
$INDV Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $4.10 up 1071.43% YoY • Reported revenue of $358M up 19.73% YoY • Indivior reaffirmed full-year 2026 financial guidance, projecting total net revenue between $1.13B and $1.2B, and Adjusted EBITDA between $535M and $575M. Indivior expects SUBLOCADE dispense unit growth in the mid-teens.
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 4:22 PM
$INDV Q4: Growth story or margin squeeze? 👀 Sublocade growth is in focus, but Suboxone pressure and the 2026 revenue outlook are just as critical. This quarter isn’t just about numbers — it’s about whether the long-term trajectory still holds. Want the full breakdown before earnings hit? Discover what’s in the cards 👉 https://www.zacks.com/stock/news/2872113/indivior-pharmaceuticals-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2872113-teaser-34240&ADID=SYND_STOCKTWITS_TWEET_2_2872113_TEASER_34240
0 · Reply
ZacksResearch
ZacksResearch Feb. 19 at 3:22 PM
$INDV saw a 282.2% rise over the past year—can it keep soaring post-earnings? 🚀 📈 Sublocade's double-digit growth 📉 Suboxone hit by generic competition 🧪 Key pipeline updates expected Find out if the rally can continue 👉 https://www.zacks.com/stock/news/2872113/indivior-pharmaceuticals-to-report-q4-earnings-whats-in-the-cards?cid=sm-stocktwits-2-2872113-body-34235&ADID=SYND_STOCKTWITS_TWEET_2_2872113_BODY_34235
0 · Reply
LarryCoakley944
LarryCoakley944 Feb. 18 at 1:48 PM
$INDV Specialty pharma with opioid treatment exposure.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 24 at 3:49 AM
$INDV Current Stock Price: $32.96 Contracts to trade: $35 INDV Feb 20 2026 Call Entry: $0.50 Exit: $0.76 ROI: 52% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
gratitude11
gratitude11 Jan. 22 at 3:36 PM
$INDV started a position here at $33.70
1 · Reply
Brockenspectre
Brockenspectre Dec. 26 at 2:37 PM
$INDV Conditions are shifting toward markets rewarding operational proof over narrative ambition. Capital allocation choices will reveal true priorities. Demonstrated durability would lengthen investor time horizons. Sentiment should follow consistency rather than noise.
0 · Reply
TalkMarkets
TalkMarkets Dec. 24 at 9:14 AM
Supply Absorbed: Watch This Accumulation Pattern Play Out $SPX $INDV $KGC $OKLO https://talkmarkets.com/content/stocks--equities/supply-absorbed-watch-this-accumulation-pattern-play-out?post=546531&userid=166882
0 · Reply
howardlindzon
howardlindzon Dec. 16 at 12:15 AM
$INDV now that fentanyl is. war crime I guess we can start dropping them on venezuela - which should be good for sales
0 · Reply